EU & US At Odds Over Merck’s Keytruda

Decisions Show How Regulators Can Differ Over Same Data

 
• By Ian Schofield

EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.

Split_Road_Signpost
Regulators sometimes take different decisions on the same drug • Source: Shutterstock

More from Europe

More from Geography